Development of recombinant vaccine for lassa fever using replication-incompetent rabies viral vector.
| Project/Area Number |
23790516
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | National Institute of Infectious Diseases |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | ウイルスベクター / ワクチン / アレナウイルス感染症 / 応用微生物 / 感染症 / ウイルス |
|---|
| Research Abstract |
Lassa fever is an acute viral illness, and there is no effective vaccine candidate available. It has been reported that cellular immunity plays the major roles in the prevention against lassa fever. Replication-incompetent live viral vaccine would be a promising vaccine candidate for lassa fever. To evaluate the immunogenicity of the replication-incompetent rhabdovirus vector for vaccine against lassa fever, we newly generated the recombinant rabies virus, delta-P-GPC strain, which lacks rabies P gene and possesses lymphocytic choriomeningitis virus (LCMV) GPC gene in its genome. We confirmed the GPC protein expression in delta-P-GPC strain infected rabies P protein expressing BHK cells by immunofluorescence assay and western blot. 80% of mice immunized twice with delta-P-GPC by i.m. and i.p. route, survived against lethal challenge with LCMV WE strain.
|
Report
(4 results)
Research Products
(12 results)
